OBSV - ObsEva SA

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.30
+0.20 (+1.98%)
As of 1:56PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.10
Open10.20
Bid10.16 x 3000
Ask10.47 x 2200
Day's Range10.07 - 10.33
52 Week Range10.01 - 20.35
Volume44,393
Avg. Volume41,874
Market Cap468.563M
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-1.97
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.57
Trade prices are not sourced from all markets
  • Wedbush: 5 Stocks On Our ‘Best Ideas List’
    TipRanks4 days ago

    Wedbush: 5 Stocks On Our ‘Best Ideas List’

    If you are looking for fresh investing inspiration, look no further. Wedbush has just released the latest version of its Best Ideas List. The June report reveals the firm's top stock picks right now- and includes the removal of two Outperform-rated names (see below). But first, let's take a closer look now at why these five stocks make such compelling investing propositions right now... 1\. Microsoft (MSFT)Top-rated Wedbush analyst Daniel Ives has just reiterated his MSFT Buy rating with a $155 price target. From current levels that indicates 18% upside potential. “In our opinion Microsoft remains in an enviable position heading into the rest of 2019 and 2020 on the heels of its cloud success and is firing on all cylinders around its Office 365 and Azure strategic vision based on our recent checks” explains the analyst. The shift to cloud is a major secular trend that is significantly benefiting MSFT, says Ives. He believes Microsoft is perfectly positioned to get more complex workloads (e.g., AI, machine learning, etc.) as more enterprises take the leap to a hybrid cloud architecture over the coming years. “While AWS remains the leader in cloud, we believe MSFT is starting to clearly "close the gap" the analyst tells investors. Indeed, roughly 32% of workloads are in the cloud today, and this figure is poised to hit a whopping 55% by 2022. View MSFT Price Target & Analyst Ratings Detail 2\. Activision Blizzard (ATVI)Wedbush isn’t the only firm signaling their confidence in ATVI right now. One of the world’s biggest video game companies, ATVI also has the thumbs up from Goldman Sachs’ Mike Ng. The Goldman Sachs analyst upgraded Activision from Hold to Buy on May 28. And he also elevated ATVI to Goldman’s ‘Conviction Buy’ list of top stock ideas. According to Ng, the company "is on the cusp of an earnings inflection" as well as an engagement inflection. "Specifically, 'Overwatch' engagement is likely to improve following the introduction of Storm Rising (PvE), Workshop mode, and Havana," the analyst told investors. "'Hearthstone' likely will benefit from Rise of Shadows (expansion) and The Dalaran Heist (solo story mode), while 'World of Warcraft' should benefit from Classic and Rise of Azshara." These create the potential for earnings upside said the analyst.He has a $54 price target on the stock (20% upside potential). In comparison, Wedbush analyst Michael Pachter has a slightly more bullish $56 price target, for 24% upside potential. See what other Top Analysts are saying about ATVI. 3\. Fidelity National Info (FIS)Mergers are shaking up the payments processing industry, and one key stock to keep your eye on is Fidelity National. FIS provides international financial services technology and outsourcing services. Wedbush analyst Moshe Katri added FIS to the firm’s Best Ideas List back in late March 2019. Since that date shares are up 10%. Katri made the move after FIS agreed to buy Worldpay (WP) for $35 billion in cash and stock. "The combined company will be positioned to offer best-in-class enterprise banking, payments, capital markets, and global e-commerce capabilities empowering merchants worldwide," the analyst commented. In short we are looking at a tech and payments powerhouse, with significant synergy potential. Katri has a $140 price target on shares (16% upside potential) calling FIS ‘significantly undervalued’ compared to peers. A similarly upbeat perspective comes from Jefferies’ Michael Del Grosso. "The consolidated entity will have global scale in both merchant processing and issuer processing," Del Grosso said. "We believe the deal's rationale is predominantly driven by continuing to drive scale in the industry.”View FIS Price Target & Analyst Ratings Detail 4\. Tempur Sealy International (TPX)Tempur Sealy International describes itself as the world's largest bedding provider. The Kentucky-based company has enjoyed a terrific rally year-to-date, with prices up 65%. And according to Wedbush’s Seth Basham this is still a stock worth buying into. He has just reiterated his Outperform rating with a $74 price target.Memorial Day weekend bricks and mortar mattress sales checks with retailers and industry contacts were favorable, noted Basham. Encouragingly, retailers called out strength in Tempur-Sealy products, with special mention of the new high-end Tempur Breeze helping to boost average selling prices (ASPs). “The favorable sales trends came despite a modest pullback in promotions across the industry. We believe TPX sales and margin trends are on track for 2Q19, with more upside than downside risk” the analyst wrote. See what other Top Analysts are saying about TPX. 5\. Electronic Arts (EA)Another gaming stock also crops up on the Best Ideas List- Electronic Arts. On May 17, the firm’s Michael Pachter promoted EA to best idea status with a $122 price target (32% upside potential).“We expect EA to deliver material upside to its FY:20 guidance for net bookings and EPS, driven by Apex Legends and a game lineup this year that appears outstanding” explained Pachter. That includes the upcoming adventure game, Star Wars Jedi: Fallen Order. The analyst added: “We expect a string of near-term catalysts, including updates on Apex MAUs, game reveals at the E3 Expo in June, greater detail on the market expansion potential for services like Google Stadia, and continuing growth of EA’s sports business.” With the E3 Expo currently underway in LA, now is the time for these catalysts to begin materializing. See what other Top Analysts are saying about EA. And it’s goodbye to:Two stocks are slashed from the list. “We are removing DIN and OBSV from the Best Ideas List” writes the firm. Dine Brands Global (DIN) operates franchised and corporate owned full-service restaurants including Applebee's Neighborhood Grill & Bar and International House of Pancakes. “While we maintain our OUTPERFORM rating, we are removing DIN from the Wedbush Best Ideas List given the less attractive risk/reward profile at current levels” explains the firm. Indeed, year-to-date DIN is trading up 39%. That’s not to say there isn’t hope ahead. “We continue to view DIN’s primarily franchised model as underappreciated and believe the current discount to franchised peers… could narrow over the next 6 to 12 months.” As for Swiss biotech Obseva (OBSV), the firm simply writes “We are removing OBSV from the Best Ideas List due to our investment price discipline.” Shares have plunged 20% year-to-date for the company, which focuses on reproductive health and pregnancy. Discover stock ideas from the Street's best performing analysts here

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of OBSV.O earnings conference call or presentation 9-May-19 12:00pm GMT

    Q1 2019 Obseva SA Earnings Call

  • GlobeNewswire13 days ago

    ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

    June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported completion of patient recruitment of IMPLANT 4 Phase 3 clinical trial of its oral oxytocin receptor antagonist, nolasiban, for the improvement of rates of pregnancy and live birth in patients undergoing embryo transfer (ET) following assisted reproduction technology (ART), or in-vitro fertilization (IVF).

  • Does The ObsEva SA (NASDAQ:OBSV) Share Price Fall With The Market?
    Simply Wall St.17 days ago

    Does The ObsEva SA (NASDAQ:OBSV) Share Price Fall With The Market?

    Anyone researching ObsEva SA (NASDAQ:OBSV) might want to consider the historical volatility of the share price...

  • GlobeNewswirelast month

    ObsEva SA to Participate in Upcoming Investor Conferences

    Geneva, Switzerland and Boston, MA – May 16, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and.

  • ObsEva SA (OBSV) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    ObsEva SA (OBSV) Q1 2019 Earnings Call Transcript

    OBSV earnings call for the period ending March 31, 2019.

  • Here’s What Hedge Funds Think About ObsEva SA (OBSV)
    Insider Monkeylast month

    Here’s What Hedge Funds Think About ObsEva SA (OBSV)

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates
    Zackslast month

    ObsEva SA (OBSV) Reports Q1 Loss, Lags Revenue Estimates

    ObsEva SA (OBSV) delivered earnings and revenue surprises of -18.00% and -50.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswirelast month

    ObsEva Reports First Quarter 2019 Financial Results

    2019 Phase 3 Data Readouts on track for nolasiban in IVF and linzagolix in uterine fibroids;                 MAA submission for nolasiban IVF therapy.

  • GlobeNewswirelast month

    ObsEva SA Announces Initiation of Phase 3 EDELWEISS 2 and 3 Trials of Linzagolix for Endometriosis Associated Pain in U.S., Canada and Europe

    Geneva, Switzerland and Boston, MA – May 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswirelast month

    ObsEva SA Announces that ObsEva’s Shareholders Approved all Board Proposals at its 2019 Annual General Meeting held on May 8, 2019

    May 8, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that ObsEva’s shareholders approved all Board proposals at its 2019 Annual General Meeting held on May 8, 2019.

  • Benzingalast month

    The Daily Biotech Pulse: Obseva Reports Positive Endometriosis Drug Trial, Assembly Biosciences Execs Depart, Coherus Settles With Amgen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Alcon AG (NYSE: ALC ) Dr.Reddy's Laboratories Ltd (NYSE: ...

  • GlobeNewswirelast month

    ObsEva SA Reports Consistent Long-Term Findings from Phase 2b EDELWEISS trial of Linzagolix for Endometriosis-Associated Pain

    Geneva, Switzerland and Boston, MA – May 3, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the.

  • GlobeNewswire2 months ago

    ObsEva SA to Hold First Quarter 2019 Financial Results and Business Update Call on May 9, 2019

    Geneva, Switzerland and Boston, MA –May 1, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and.

  • GlobeNewswire2 months ago

    ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

    April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced additional neonatal and infant follow-up results from the IMPLANT2 Phase 3 trial of its oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF procedures. “We are very pleased by the results from the follow-up of the babies born in the IMPLANT2 trial, which is consistent with prior pre-clinical and clinical data indicating that the safety of nolasiban administered at the time of embryo transfer is no different from placebo,” said Dr. Ernest Loumaye, Co-Founder and Chief Executive Officer of ObsEva.

  • GlobeNewswire3 months ago

    Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

    Geneva, Switzerland and Boston, MA – March 29, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of OBSV.O earnings conference call or presentation 5-Mar-19 1:00pm GMT

    Q4 2018 Obseva SA Earnings Call

  • GlobeNewswire3 months ago

    ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

    Geneva, Switzerland and Boston – March 13, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and.

  • ObsEva SA (OBSV) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    ObsEva SA (OBSV) Q4 2018 Earnings Conference Call Transcript

    OBSV earnings call for the period ending December 31, 2018.

  • GlobeNewswire3 months ago

    ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update

    March 5, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported financial results for the fourth quarter and the year ending December 31, 2018. It has also provided a business update outlining recent corporate progress and upcoming milestones.

  • GlobeNewswire4 months ago

    ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

    Geneva, Switzerland and Boston, MA –February 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and.

  • Are ObsEva SA’s (NASDAQ:OBSV) Interest Costs Too High?
    Simply Wall St.4 months ago

    Are ObsEva SA’s (NASDAQ:OBSV) Interest Costs Too High?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The direct benefit for ObsEva SA (NASDAQ:OBSV), which sports aRead More...

  • GlobeNewswire5 months ago

    ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

    January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced the completion of Part A of the PROLONG trial in preterm labor. In this trial, OBE022 was administered daily for 7 days, to pregnant women, who were already receiving standard of care therapy for preterm labour, atosiban infusion for 48 hours. The goal was to assess the safety and pharmacokinetics of OBE022 in patients.